Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Tillman

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 6, 2024
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 StudyStephen A Harrison, Juan P Frias, K Jean Lucas, et al.
Lancet (London, England)|August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialMazen Noureddin, Juan P Frias, Guy W Neff, et al.
JAMA Network Open|September 7, 2019
Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary AnalysisMary Farrant, J Donald Easton, Eric E Adelman, et al.
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|December 8, 2011
Description of International Caenorhabditis elegans Experiment first flight (ICE-FIRST)N J Szewczyk, J Tillman, C A Conley, et al.
The Lancet. Gastroenterology & Hepatology|October 6, 2023
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Juan P Frias, Guy Neff, et al.
The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 6, 2024
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 StudyStephen A Harrison, Juan P Frias, K Jean Lucas, et al.
Lancet (London, England)|August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialMazen Noureddin, Juan P Frias, Guy W Neff, et al.
JAMA Network Open|September 7, 2019
Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary AnalysisMary Farrant, J Donald Easton, Eric E Adelman, et al.
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|December 8, 2011
Description of International Caenorhabditis elegans Experiment first flight (ICE-FIRST)N J Szewczyk, J Tillman, C A Conley, et al.
The Lancet. Gastroenterology & Hepatology|October 6, 2023
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Juan P Frias, Guy Neff, et al.
The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
Pageof 8